Celiac Panel Interpretation by Decade of Life

What the Celiac Panel Actually Measures

A celiac panel is not a single test. It is a set of serological markers, each targeting a different immunological pathway triggered by gluten exposure in genetically susceptible individuals.

Understanding what each marker does prevents misinterpretation, especially when one result is elevated and others are not.

tTG-IgA: The Workhorse

Tissue transglutaminase IgA is the antibody produced against the enzyme tTG-2, which modifies gliadin peptides and amplifies the immune response in the intestinal mucosa. A 2020 systematic review in The Lancet Gastroenterology and Hepatology summarized tTG-IgA sensitivity at roughly 92 to 96% and specificity at 94 to 97% in adults on a gluten-containing diet. [1]

The result is reported as a number (for example, 4 U/mL) alongside a laboratory-specific ULN, typically 4 to 10 U/mL depending on the assay platform. A value above the ULN is "positive." A value more than 10 times the ULN carries a separate clinical weight, discussed below.

EMA-IgA: The Confirmatory Marker

Endomysial antibody IgA is nearly 100% specific for celiac disease in most published cohorts, but it requires indirect immunofluorescence on primate esophagus or human umbilical cord tissue, making it observer-dependent and costlier. It is not a screening test. It confirms a positive tTG-IgA or elevates confidence before a biopsy decision. [2]

DGP-IgG: The IgA-Deficient Patient's Test

Deamidated gliadin peptide IgG is the preferred marker when total IgA is low or undetectable. Its sensitivity in IgA-deficient populations is approximately 80% for celiac disease. A 2013 study in Clinical Gastroenterology and Hepatology found DGP-IgG outperformed native gliadin antibodies (AGA-IgG) in this subset. [3]

Total IgA: The Validity Check

Total serum IgA must always be measured alongside celiac-specific IgA markers. If total IgA is <7 mg/dL in adults (or below the age-specific lower limit in children), IgA-based results are uninterpretable and DGP-IgG or tTG-IgG should be substituted.

Decade-by-Decade Interpretation Guide

Age reshapes both the immune system and the pre-test probability of celiac disease. The same tTG-IgA value of 12 U/mL (just above a ULN of 10 U/mL) has a different positive predictive value at age 2 than at age 55.

Ages 0 to 2 Years: IgA Immaturity Dominates

Children under 2 years have not yet reached adult IgA secretory capacity. Serum IgA levels may be physiologically low, rendering tTG-IgA and EMA-IgA falsely negative or uninterpretable. The American College of Gastroenterology (ACG) 2023 guidelines state: "In children younger than 2 years of age, DGP-IgG should be added to the panel given the immaturity of the IgA system." [4]

Celiac disease does present in this group, often as failure to thrive, chronic diarrhea, or abdominal distension after gluten introduction. A negative tTG-IgA in a symptomatic 18-month-old is not reassuring without a concurrent DGP-IgG and total IgA.

The 2020 ESPGHAN guidelines permit a biopsy-free diagnosis in children (including toddlers) only when tTG-IgA exceeds 10x ULN AND EMA-IgA is separately positive AND HLA-DQ2/DQ8 is confirmed. [5] That triple requirement exists precisely because antibody assays are less reliable at this age.

Ages 2 to 12 Years: Highest Seroconversion Rate

School-age children carry the highest per-capita rate of new seroconversion. A 2020 prospective cohort study of 6,757 children in The New England Journal of Medicine (TEDDY trial) found celiac autoimmunity (defined as persistent tTG-IgA positivity) appeared in 9.1% of HLA-high-risk children by age 6. [6]

In this age group, a tTG-IgA more than 10x ULN combined with a positive EMA-IgA satisfies the ESPGHAN criteria for a no-biopsy diagnosis in symptomatic children with confirmed HLA-DQ2 or DQ8. A tTG-IgA of 1.1 to 3x ULN is a "gray zone" that warrants repeat testing at 3 to 6 months on a confirmed gluten-containing diet before any further workup.

Optimal range in this decade: tTG-IgA undetectable or below ULN on a gluten-free diet after 12 months of strict adherence. Persistent elevation after 12 months suggests ongoing gluten exposure, typically inadvertent.

Ages 13 to 17 Years: Adolescent Adherence and Atypical Presentations

Teenagers with known celiac disease show significantly worse serological normalization than younger children. A 2016 study in Journal of Pediatric Gastroenterology and Nutrition found 40% of adolescents maintained elevated tTG-IgA at 2-year follow-up compared with 18% of children under 12, attributed primarily to poor diet adherence. [7]

New diagnoses in this decade often present atypically: fatigue, short stature, delayed puberty, or iron deficiency anemia rather than classic diarrhea. A tTG-IgA in the 1 to 3x ULN range in an adolescent with unexplained iron deficiency or ferritin <15 ng/mL warrants full celiac workup including EMA-IgA and duodenal biopsy regardless of the modest elevation.

Ages 18 to 39 Years: Classic Presentation and Fertility Implications

Adults in their 20s and 30s are diagnosed most often through iron deficiency anemia workup or after a first-degree relative is diagnosed. The ACG 2023 guideline recommends serological screening in all first-degree relatives of confirmed celiac patients. [4]

Ferritin is often the first lab to flag. Up to 46% of newly diagnosed celiac adults present with iron deficiency anemia, and the bowel damage preferentially affects the proximal duodenum where iron and folate are absorbed.

Women in this decade deserve specific attention. Undiagnosed celiac disease has been associated with recurrent pregnancy loss and subfertility. The European Society for Human Reproduction and Embryology (ESHRE) guideline on recurrent pregnancy loss (2022) lists celiac screening as a consideration in the workup, though evidence for a causal link remains debated. [8]

Optimal tTG-IgA in this decade: below ULN on a gluten-containing diet (i.e., the panel is negative), or undetectable after 12 to 24 months on a strict gluten-free diet.

Ages 40 to 59 Years: Overlap with Hypothyroidism and Other Autoimmune Conditions

Midlife is when celiac disease increasingly presents with non-GI symptoms. Autoimmune thyroid disease co-occurs in 14 to 26% of celiac patients, and the overlap is bidirectional. A 2018 meta-analysis in Thyroid (N=22 studies) found celiac disease prevalence in Hashimoto's thyroiditis patients to be approximately 3.4x higher than background population rates. [9]

Any adult in this decade with Hashimoto's thyroiditis, type 1 diabetes, or primary biliary cholangitis who has unexplained iron, B12, or folate deficiency should have a full celiac panel regardless of GI symptoms.

A tTG-IgA in the gray zone (1 to 3x ULN) in a patient with a co-existing autoimmune condition deserves more aggressive follow-up than the same value in an otherwise healthy person. EMA-IgA confirmation and HLA typing narrow the differential before committing to an endoscopy.

Ages 60 to 79 Years: False Negatives Increase, Consequences Are Greater

Immunosenescence reduces antibody production across the board. Older adults with confirmed celiac disease on biopsy sometimes carry tTG-IgA values below the assay ULN. A 2019 study in Alimentary Pharmacology and Therapeutics found that 17% of biopsy-confirmed celiac patients over age 65 had a tTG-IgA within the normal range at diagnosis. [10]

The clinical stakes are higher in this decade. Untreated celiac in older adults carries a meaningfully elevated risk of enteropathy-associated T-cell lymphoma (EATL), osteoporosis, and fractures. A 2018 cohort study in Gut (N=7,966 celiac patients) found the risk of EATL was highest in patients diagnosed after age 65 who did not adhere to a gluten-free diet. [11]

Practically: if an older adult has villous atrophy on biopsy but a negative celiac antibody panel, do not dismiss the serologic data without HLA typing. HLA-DQ2 or DQ8 negativity genuinely argues against celiac disease; positivity keeps it firmly on the differential even with a seronegative picture.

Ages 80 and Older: Seronegative Celiac Is the Rule to Expect

The combination of immunosenescence, polypharmacy-related mucosal injury (NSAIDs, PPIs), and reduced gluten intake in older adults with anorexia means the celiac panel may be nearly uninformative in the oldest old.

Bone density loss, refractory anemia, and unexplained weight loss in an 80-year-old may still have celiac disease as an underlying cause even with a completely normal celiac panel. Biopsy remains the diagnostic gold standard. The British Society of Gastroenterology 2014 guidelines note that serological tests have reduced sensitivity in older populations and that endoscopy with duodenal biopsy should be pursued if clinical suspicion remains. [12]

What "Optimal" Actually Means for Each Marker

The word "optimal" has two distinct meanings in celiac testing, and conflating them causes errors.

Optimal screening result (pre-diagnosis): Every marker below the laboratory ULN in a person consuming at least 3 grams of gluten per day (roughly 2 slices of bread). A negative panel on adequate gluten exposure reliably excludes active celiac disease in most adults under 65. That confidence drops progressively above age 65.

Optimal monitoring result (post-diagnosis, on a gluten-free diet): tTG-IgA should become undetectable or below the assay's lower limit of quantification within 12 to 24 months of strict gluten avoidance. ESPGHAN 2020 defines mucosal healing targets as Marsh 0 to 1 on repeat biopsy, and normalization of tTG-IgA to below ULN correlates moderately well with mucosal recovery, though the correlation is imperfect. [5]

A tTG-IgA that plateaus at 1.5 to 2x ULN after 18 months on a supposedly strict gluten-free diet should prompt dietary review by a celiac-trained dietitian, repeat biopsy to assess Marsh grade, and a review for refractory celiac disease type I or II.

The 10x ULN Threshold: Why It Matters

A tTG-IgA above 10x ULN has a positive predictive value of approximately 95 to 99% for biopsy-confirmed celiac disease in children and adults alike. ESPGHAN 2020 codified this into a no-biopsy pathway for pediatric patients. The ACG 2023 guidelines acknowledge the same threshold in adults but stop short of recommending routine biopsy omission, citing variability between assay platforms. [4,5]

Practically, if your result comes back at 10x ULN or higher, a second confirmatory test (EMA-IgA) and a dietitian-supervised gluten-free diet trial may be initiated without waiting for endoscopy in selected adult cases. Discuss this with your gastroenterologist.

Gray-Zone Results (1 to 3x ULN)

Gray-zone tTG-IgA values are common and frequently overinterpreted in both directions.

Causes of low-positive tTG-IgA unrelated to celiac disease include type 1 diabetes, inflammatory bowel disease, heart failure, psoriasis, and chronic liver disease. The ACG 2023 guidelines recommend EMA-IgA confirmation and/or endoscopic biopsy for any tTG-IgA in the 1 to 3x ULN range before a celiac diagnosis is made. [4]

Celiac Panel and Key Nutrient Deficiencies

The proximal small intestine, the duodenum and upper jejunum, absorbs iron, folate, calcium, and fat-soluble vitamins. Celiac-related villous atrophy therefore produces a predictable deficiency signature.

Iron, Ferritin, and B12

Iron deficiency is the most common extra-intestinal manifestation of celiac disease in adults. Ferritin below 30 ng/mL in the absence of obvious blood loss warrants celiac screening. Vitamin B12 deficiency is less common because the terminal ileum, often spared in early celiac disease, absorbs B12. When B12 is low alongside iron and folate deficiency in the same patient, consider a more extensive mucosal lesion or an additional diagnosis such as autoimmune gastritis (pernicious anemia) co-existing with celiac disease.

Calcium and Bone Density

Low calcium and secondary hyperparathyroidism from fat malabsorption impair bone mineralization. Adults diagnosed with celiac disease at age 40 or older should have a DEXA scan at diagnosis. A 2014 meta-analysis in the Journal of Bone and Mineral Research found celiac patients had a 37% higher fracture risk than controls (relative risk 1.37, 95% CI 1.17 to 1.59), with the excess concentrated in the hip and spine. [13]

Hypothyroid Overlap: A Two-Way Street

Levothyroxine absorption depends on an intact duodenal mucosa. Celiac disease impairs levothyroxine absorption, causing apparent thyroid hormone resistance. An adult with Hashimoto's hypothyroidism whose TSH remains elevated despite adequate levothyroxine doses should have a celiac panel before the clinician increases the thyroid medication dose. Resolution of villous atrophy on a gluten-free diet often allows a dose reduction. [9]

Testing Pitfalls and How to Avoid Them

Gluten-Free Diet Before Testing

The single most common testing error is performing a celiac panel after the patient has already started a gluten-free diet. Antibodies fall within 3 to 6 months of gluten removal. A negative result in this context is uninterpretable.

The ACG 2023 guidelines recommend a "gluten challenge" of at least 3 grams per day for 6 to 8 weeks before serological testing in adults who have been gluten-free for more than 3 months. [4] In patients who have been gluten-free for years, HLA-DQ2/DQ8 testing is a reasonable alternative because negative HLA essentially excludes celiac disease (negative predictive value >99%).

IgA Deficiency Masking a Positive

Total IgA below 7 mg/dL (adults) renders tTG-IgA and EMA-IgA uninterpretable. IgA deficiency is roughly 10 to 15 times more common in celiac disease than in the general population. Always check total IgA on the same draw.

Assay Platform Variation

TTG-IgA is not a standardized assay. Different laboratories use different kits with different ULNs (ranging from 4 to 20 U/mL) and different units (U/mL, AU/mL, IU/mL). Serial monitoring should use the same laboratory and same platform. A "decrease" from 18 U/mL to 10 U/mL may reflect diet adherence or simply a change in laboratory vendor.

When to Retest and How Often

For adults newly diagnosed with celiac disease, the British Society of Gastroenterology recommends repeat tTG-IgA at 6 and 12 months after initiating a gluten-free diet, then annually. [12] Children typically retest at 6 months and again at 12 to 24 months.

A tTG-IgA that has normalized to below ULN and remains there for two consecutive annual checks may be monitored less frequently in low-risk adults with no symptoms. A persistently elevated tTG-IgA after 24 months on a gluten-free diet should trigger biopsy to assess Marsh grade and rule out refractory disease.

The American Gastroenterological Association (AGA) Institute recommends against routine repeat biopsy in asymptomatic adults whose tTG-IgA has normalized, citing low yield when serology is consistently negative. [14]